GlassScriptPhysician profile
Payal V Dixit
NPI 1457646549
$9,234.35
in general payments reported to CMS, 2019-2025
33 companies · $608 in 2025
The $608 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,566 · 2020: $477 · 2021: $1,595 · 2022: $1,804 · 2023: $1,071 · 2024: $1,113 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,792.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,901.42 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,597.85 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $774.18 | 2019-2025 | Dupixent |
| Galderma Laboratories, L.P. | $697.62 | 2019-2025 | Nemluvio |
| Janssen Biotech, INC. | $520.29 | 2019-2024 | Tremfya |
| Genzyme Corporation | $437.25 | 2019-2022 | |
| Lilly USA, LLC | $421.56 | 2019-2024 | Olumiant, Taltz |
| Incyte Corporation | $372.07 | 2022-2025 | Opzelura |
| Amgen INC. | $292.54 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $230.28 | 2019-2024 | |
| Celgene Corporation | $221.92 | 2019 | |
| Leo Pharma INC. | $217.26 | 2019-2024 | Adbry |
| Sun Pharmaceutical Industries INC. | $215.58 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $209.97 | 2019-2025 | Cabtreo |
| Genentech USA, INC. | $207.31 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $196.89 | 2023-2025 | Sotyktu |
| Ucb, INC. | $159.56 | 2019-2023 | Cimzia |
| Allergan, INC. | $99.80 | 2022 | |
| Janssen Scientific Affairs, LLC | $92.25 | 2019 | |
| Biofrontera INC. | $65.72 | 2019-2025 | Xepi, Bf-Rhodoled, Rhodoled Xl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.30 | 2024 | Spevigo |
| Vyne Pharmaceuticals INC. | $39.93 | 2020-2021 | |
| Almirall LLC | $30.29 | 2019-2020 | |
| Medimetriks Pharmaceuticals, INC. | $24.36 | 2021 | |
| Stryker Corporation | $23.93 | 2023 | Surpass Evolve |
| Dermira, INC. | $19.43 | 2019 | |
| Epi Health, LLC | $19.17 | 2021 | |
| Botanix Sb INC | $17.38 | 2025 | Sofdra |
| Dusa Pharmaceuticals, INC. | $17.12 | 2019 | |
| Mayne Pharma Commercial LLC | $16.29 | 2023 | |
| Sanofi-Aventis U.S. LLC | $15.15 | 2019 | |
| Dermavant Sciences, INC. | $14.82 | 2024 | Vtama |
| Boston Scientific Corporation | $13.86 | 2025 | Embold Fibered |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Payal Dixit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.